{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 25,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline-based pipeline layout to show the progression of two drug candidates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/5",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.38,
        "x": 0.345,
        "y": 0.335
      },
      "kind": "diagram",
      "text": "Fast Track Designation arrow for NXP800; Phase 1a Initiated arrow for NXP900",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d73c24c-113f-4bf3-84a0-af8cd1307233",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.02,
        "y": 0.83
      },
      "kind": "disclaimer",
      "text": "a. Exclusive worldwide rights acquired from the Institute of Cancer Research, UK. b. Exclusive worldwide rights acquired from the University of Edinburgh",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1eed1b9a-98b0-4071-bca9-9b47f51987e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.21,
        "x": 0.74,
        "y": 0.465
      },
      "kind": "image",
      "text": "ENGOT and GOG Foundation logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65eaf7ad-3719-4088-bdb9-7d0717962b83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.96,
        "x": 0.02,
        "y": 0.232
      },
      "kind": "table",
      "text": "Drug Candidate, Indication, Discovery and Lead Optimization, IND-Enabling, Phase 1a, Phase 1b, Phase 2, Phase 3",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bac1ecc-3045-4431-bba4-d599da0bf8e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Nuvectis Precision Medicine Pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9613df4-0e76-49b3-be32-75e4efef3250",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "6ad083da-5344-4951-ab4c-e73e3c543a6e",
      "evidence": "Pipeline timeline visualization",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 4,
      "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
      "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
      "position": 0,
      "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}